Form 4 Filing for Adaptive Biotechnologies Corp - Officer Stock Sale

Harlan S Robins, Chief Scientific Officer of Adaptive Biotechnologies Corp, reported a sale of 10,000 shares of Common Stock on April 8, 2026, executed under a Rule 10b5-1 trading plan. The shares were sold at a weighted-average price of $14.85 per share, with individual transactions ranging from $14.65 to $15.06. Following this transaction, Mr. Robins directly owns 1,512,058 shares of the company's stock. The filing was signed by Kyle Piskel as Attorney-in-Fact on April 10, 2026.